<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683055</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17300506</org_study_id>
    <nct_id>NCT04683055</nct_id>
  </id_info>
  <brief_title>Phaco-Trabeculotomy Vs Phaco-Trabeculectomy</brief_title>
  <acronym>PDT vs PT</acronym>
  <official_title>Phacoemulsification Combined With Trabeculectomy Versus Phacoemulsification Combined With Trabeculotomy for Treatment of Chronic Angle Closure Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized comparative study on adult patients with synechial angle closure&#xD;
      glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized into two groups: group A : patients will undergo two site&#xD;
      phacoemulfication combined with trabeculectomy Group B with Phacoemulsification combined with&#xD;
      ab-externo trabeculotomy. Preoperative assessments including full ophthalmic examination,&#xD;
      anterior segment Optical Coherence Tomography (OCT) of the angle , endothelial cell count ,&#xD;
      visual fiend Perimetry and Biometry. Patients were followed up: first day, first week and&#xD;
      every two months for 6 month. We will compare adverse effects and outcomes in both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Success</measure>
    <time_frame>1,3,6 months</time_frame>
    <description>Reduction of IOP more than 30% on no glaucoma drops</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual outcome</measure>
    <time_frame>1,3,6 month</time_frame>
    <description>Uncorrected visual acuity by Snellen's chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 week, 1 month, 3 months, 6 months</time_frame>
    <description>all intraoperative and postoperative adverse events witt be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ophthalmopathy</condition>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Angle-Closure</condition>
  <arm_group>
    <arm_group_label>Phacoemulsification combined with trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo Two site phacoemulsification combined with trabeculectomy with Mitomycin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsificaiton combined with ab-externo trabeculotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo two phacoemulsification combined with deep sclerectomy and ab-externo trabeculotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification combined with trabeculectomy</intervention_name>
    <description>Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision</description>
    <arm_group_label>Phacoemulsification combined with trabeculectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsificaiton combined with ab-externo trabeculotomy</intervention_name>
    <description>Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision</description>
    <arm_group_label>Phacoemulsificaiton combined with ab-externo trabeculotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with chronic angle closure glaucoma, with or without peripheral anterior&#xD;
        synechiae, age more than 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable for follow up&#xD;
&#xD;
          -  Patients with corneal or retinal disease that affects visual outcome of surgery&#xD;
&#xD;
          -  Patients with previous glaucoma procedure in the eye of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University Hospital</name>
      <address>
        <city>Assiut</city>
        <zip>7125</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001 Nov;108(11):1943-53.</citation>
    <PMID>11713061</PMID>
  </reference>
  <reference>
    <citation>Rebolleda G, Muñoz-Negrete FJ. Phacoemulsification in eyes with functioning filtering blebs: a prospective study. Ophthalmology. 2002 Dec;109(12):2248-55.</citation>
    <PMID>12466166</PMID>
  </reference>
  <reference>
    <citation>Hansapinyo L, Choy BNK, Lai JSM, Tham CC. Phacoemulsification Versus Phacotrabeculectomy in Primary Angle-closure Glaucoma With Cataract: Long-Term Clinical Outcomes. J Glaucoma. 2020 Jan;29(1):15-23. doi: 10.1097/IJG.0000000000001397.</citation>
    <PMID>31702714</PMID>
  </reference>
  <reference>
    <citation>Töteberg-Harms M, Wachtl J, Schweier C, Funk J, Kniestedt C. Long-term efficacy of combined phacoemulsification plus trabeculectomy versus phacoemulsification plus excimer laser trabeculotomy. Klin Monbl Augenheilkd. 2017 Apr;234(4):457-463. doi: 10.1055/s-0043-100291. Epub 2017 Mar 6.</citation>
    <PMID>28264221</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mahmoud F. Rateb</investigator_full_name>
    <investigator_title>Assitant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data in the study , after completion after de-identification</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>after publication and for five years</ipd_time_frame>
    <ipd_access_criteria>Anyone who wants to access data</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

